Neuralink Reports First Clinical Trial Results: Paralyzed Patients Control Devices With Thought Alone
Neuralink has released the first peer-reviewed results from its PRIME (Precise Robotically Implanted Brain-Computer Interface) clinical trial, and the data is drawing attention from both the medical community and the broader tech industry. The study, published in the New England Journal of Medicine, documents outcomes for eight patients with spinal cord injuries who received Neuralink's N2 brain implant over the past 18 months.
The Results
All eight participants in the trial were able to control a computer cursor within 24 hours of the device being activated. Within two weeks, six of the eight achieved typing speeds exceeding 30 words per minute using thought alone — no physical movement required. Two participants reached 42 words per minute, approaching the average speed of someone typing on a smartphone.
Beyond cursor control, four participants were enrolled in an extended protocol involving a robotic arm. Three of the four successfully completed a standardized dexterity test, picking up objects of varying sizes and placing them at specific locations. The fourth participant achieved partial control but struggled with fine motor tasks.
"These results are clinically meaningful," said Dr. Jaimie Henderson, a Stanford neurosurgeon and Neuralink advisor. "We're not talking about moving a cursor left or right. These patients are browsing the web, writing emails, and in some cases operating assistive robotic hardware with a level of fluency we haven't seen from any previous BCI system."
How the N2 Implant Works
The N2 is a coin-sized device implanted flush with the skull, with 1,024 electrodes threaded into the motor cortex by Neuralink's R1 surgical robot. The electrodes record neural activity associated with intended movement, and an onboard chip processes these signals in real time before transmitting them wirelessly to a nearby receiver connected to a computer.
Compared to earlier brain-computer interfaces developed in academic settings — most notably BrainGate, which has been in research trials since 2004 — the N2 offers significantly higher electrode density and a fully wireless design. BrainGate's system uses a pedestal connector that protrudes through the skull, creating infection risk and limiting patient mobility.
Neuralink's surgical robot is another differentiator. The R1 performs the electrode implantation autonomously, threading each wire between blood vessels to minimize tissue damage. The company reports that average surgery time has dropped to under 45 minutes, with all eight patients discharged within 48 hours.
Safety Profile
The safety data is encouraging but not without caveats. No serious adverse events were reported during the trial period. Two patients experienced minor headaches in the first week following implantation, which resolved without intervention. One patient required a software update to recalibrate electrode readings after signal quality degraded in the third month, a procedure performed wirelessly without additional surgery.
However, the trial's 18-month follow-up period is relatively short for an implanted medical device. Long-term questions about electrode stability, tissue scarring, and device longevity remain unanswered. Previous BCI research has shown that electrode signal quality can degrade over several years as the brain's immune response encapsulates the foreign material.
Neuralink says the N2 is designed for a minimum operational life of 10 years, but that claim cannot be verified until patients have carried the device for that duration.
Regulatory and Ethical Landscape
The FDA granted Neuralink breakthrough device designation in 2023, which streamlined the approval process for clinical trials. The current trial is a Phase 1 safety study with a small sample size, and a broader Phase 2 trial involving up to 50 patients is planned for later in 2026.
Regulatory approval for commercial use remains years away. The FDA will require extensive safety and efficacy data before allowing the N2 to be marketed as a treatment for paralysis. Competing companies including Synchron, which uses a less invasive stent-based approach, and Blackrock Neurotech are also advancing clinical programs.
Ethical debates continue around the technology. Privacy advocates have raised concerns about the security of neural data, and disability rights organizations have pushed back against framing paralysis as a problem that needs to be "solved" rather than accommodated. Neuralink has published a data privacy framework but has not submitted it for independent audit.
What Comes Next
Neuralink CEO Elon Musk has publicly stated the company's long-term goal extends beyond medical applications to creating a general-purpose brain-computer interface for healthy individuals. That vision remains speculative and faces enormous scientific, regulatory, and ethical hurdles.
For now, the clinical results represent a concrete milestone. The N2 is the most capable implanted BCI yet demonstrated in human patients, and the trial data will likely accelerate the broader field regardless of Neuralink's commercial trajectory.
